Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
评估爵士制药：来自7位金融分析师的见解
In the last three months, 7 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ), offering a diverse range of perspectives from bullish to bearish.
在过去的三个月中，7位分析师公布了对Jazz Pharmicals（纳斯达克股票代码：JAZZ）的评级，提供了从看涨到看跌的不同视角。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表总结了他们最近的评估，说明了过去30天不断变化的情绪，并将其与前几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $184.86, a high estimate of $222.00, and a low estimate of $113.00. Experiencing a 6.73% decline, the current average is now lower than the previous average price target of $198.20.
在对12个月目标股价的评估中，分析师公布了对Jazz Pharmicals的见解，平均目标股价为184.86美元，最高估计为222.00美元，最低估计为113.00美元。目前的平均价格下降了6.73％，现在低于之前的平均目标股价198.20美元。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析师评级：深度分析
A clear picture of...
通过对分...
登录免费看全文
登录/注册